Finance

Lists
Outlook: 57.1% bullish·0.0% bearish
Go to analysis
ORKA:NASDAQ
Oruka Therapeutics Inc
$96.87
+0.23%
(+0.22) 1D
$96.50
-0.38% (-0.37)
After hours
Closed: Oct 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORKA...
Open
$94.87
High
$97.60
Low
$94.74
Mkt. cap
6.41B
Avg. vol.
1.03M
Volume
634.04K
52-wk high
$115.51
52-wk low
$25.23
EPS
-$2.46
Beta
-0.40
Shares outstanding
66.21M
No. of employees
68
Open
$94.87
High
$97.60
Low
$94.74
Mkt. cap
6.41B
Avg. vol.
1.03M
Volume
634.04K
52-wk high
$115.51
52-wk low
$25.23
EPS
-$2.46
Beta
-0.40
Shares outstanding
66.21M
No. of employees
68
News stories
From web sources and news partners
About Oruka Therapeutics Inc
CEO-
Employees68
Founded2024
HeadquartersWestminster, Colorado, United States
SectorBiotechnology
Websiteorukatx.com
Analyst ratings
Based on 12 analysts giving stock ratings to ORKA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ORKA in the last 3 months.
Highest
Current $96.87
$200.00 (+106.46%)
Average
$151.90 (+56.81%)
Lowest
$105.00 (+8.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Risinger
Leerink Partners
Buy
Reiterated
-
-
10/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$165.00
+70.3%
10/27/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$120.00
+23.9%
10/27/2026
Etzer Darout
Barclays
Buy
Maintained
$160.00
+65.2%
10/27/2026
Julian Harrison
BTIG
Buy
Reiterated
$151.00
+55.9%
10/26/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$105.00
+8.4%
10/26/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$180.00
+85.8%
10/07/2026
Martin Fan
Wedbush
Buy
Maintained
$165.00
+70.3%
09/24/2026
David Nierengarten
Wedbush
Buy
Maintained
$165.00
+70.3%
09/24/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$175.00
+80.7%
09/23/2026
Michael Yee
UBS
Buy
Maintained
$130.00
+34.2%
09/01/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/26/2026
Roger Song
Jefferies
Buy
Maintained
$133.00
+37.3%
08/11/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$200.00
+106.5%
08/10/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$150.00
+54.8%
06/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.99M
27.64M
29.14M
43.26M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.12M
6.79M
7.29M
6.85M
Operating expense
34.10M
34.43M
36.43M
50.11M
Total operating expenses
34.10M
34.43M
36.43M
50.11M
Operating income
-34.10M
-34.43M
-36.43M
-50.11M
Other non operating income
-4.00K
-1.00K
8.00K
4.00K
EBT including unusual items
-30.28M
-29.58M
-31.82M
-41.21M
EBT excluding unusual items
-30.28M
-29.58M
-31.82M
-41.21M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-30.28M
-29.58M
-31.82M
-41.21M
Net profit margin
-
-
-
-
Earnings per share
-0.55
-0.45
-0.48
-0.55
Interest and investment income
3.83M
4.85M
4.61M
8.90M
Interest expense
-
-
-
-
Net interest expenses
3.83M
4.85M
4.61M
8.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.08M
-34.40M
-36.39M
-50.06M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps